Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who star...
Saved in:
| Published in | PloS one Vol. 16; no. 5; p. e0250820 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
18.05.2021
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0250820 |
Cover
| Abstract | Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.
This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.
A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up.
Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity. |
|---|---|
| AbstractList | Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019. This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits. A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up. Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity. About the Authors: Viktoria Papp Roles Conceptualization, Data curation, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing * E-mail: papp.vittoria@gmail.com Affiliation: Odense University Hospital, Odense, Denmark ORCID logo https://orcid.org/0000-0001-9968-549X Mathias Due Buron Roles Conceptualization, Methodology, Validation, Writing – review & editing Affiliations The Danish Multiple Sclerosis Registry, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark, Danish Multiple Sclerosis Center, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark Volkert Siersma Roles Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing Affiliation: The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark Peter Vestergaard Rasmussen Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Aarhus University Hospital, Aarhus, Denmark Zsolt Illes Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Odense University Hospital, Odense, Denmark Matthias Kant Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Hospital of Southern Jutland, Sønderborg, Denmark Claudia Hilt Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Aalborg University Hospital, Aalborg, Denmark Zsolt Mezei Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Aalborg University Hospital, Aalborg, Denmark Homayoun Roshanisefat Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Slagelse/Odense University Hospital, Odense, Denmark ORCID logo https://orcid.org/0000-0002-3019-8826 Tobias Sejbæk Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Department of Neurology, Hospital of South West Jutland, Esbjerg, Denmark ORCID logo https://orcid.org/0000-0002-7682-2188 Arkadiusz Weglewski Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark Janneke van Wingerden Roles Funding acquisition, Writing – original draft, Writing – review & editing Affiliation: Sanofi, Amsterdam, The Netherlands Svend Sparre Geertsen Roles Funding acquisition, Writing – original draft, Writing – review & editing Affiliation: Sanofi, Copenhagen, Denmark ORCID logo https://orcid.org/0000-0003-4497-3616 Stephan Bramow Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Danish Multiple Sclerosis Center, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark ORCID logo https://orcid.org/0000-0001-9482-1771 Finn Sellebjerg Roles Investigation, Writing – original draft, Writing – review & editing Affiliation: Danish Multiple Sclerosis Center, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark Melinda Magyari Roles Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing Affiliations The Danish Multiple Sclerosis Registry, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark, Danish Multiple Sclerosis Center, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark Introduction Teriflunomide (Aubagio®) 14 mg is a once-daily, oral disease-modifying therapy (DMT) approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) [1] or relapsing forms of multiple sclerosis (RMS) [2] in more than 80 countries. The Kurtzke Expanded Disability Status score (EDSS) and Functional Systems Scores are reported at treatment initiation and at scheduled visits thereafter, while discontinuation, side effects, treatment switching, and relapses are recorded along with corresponding dates. Patient parameters assessed at the start of teriflunomide treatment, used as covariates in the statistical analyses, were demographics (age, sex), and MS disease-specific data: diagnosis (RRMS, CIS), disease duration (diagnosis and onset), number of relapses in the previous year, annualized relapse rate (ARR) at teriflunomide treatment start that counts the number of relapses in the year prior to teriflunomide treatment start. Categorization of previously administered DMTs For previously treated patients, the DMTs they received were categorized as ‘Moderate efficacy’ (teriflunomide, interferon beta-1a IM., glatiramer acetate, interferon beta-1b, peginterferon beta-1a, interferon beta-1a SC., dimethyl fumarate) or ‘High efficacy’ (fingolimod, alemtuzumab, rituximab, cladribine, mitoxantrone, ocrelizumab, natalizumab, ofatumumab, daclizumab) [30]. Objective Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019. Methods This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits. Results A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up. Conclusions Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity. Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019. This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits. A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up. Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity. ObjectiveTeriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.MethodsThis was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.ResultsA total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up.ConclusionsSolid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity. Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.OBJECTIVETeriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.METHODSThis was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up.RESULTSA total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up.Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.CONCLUSIONSSolid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity. |
| Audience | Academic |
| Author | Rasmussen, Peter Vestergaard Siersma, Volkert Weglewski, Arkadiusz Kant, Matthias Magyari, Melinda Illes, Zsolt Sejbæk, Tobias Geertsen, Svend Sparre Papp, Viktoria van Wingerden, Janneke Sellebjerg, Finn Buron, Mathias Due Roshanisefat, Homayoun Hilt, Claudia Mezei, Zsolt Bramow, Stephan |
| AuthorAffiliation | 1 Odense University Hospital, Odense, Denmark 6 Hospital of Southern Jutland, Sønderborg, Denmark 7 Aalborg University Hospital, Aalborg, Denmark 9 Department of Neurology, Hospital of South West Jutland, Esbjerg, Denmark 5 Aarhus University Hospital, Aarhus, Denmark 4 The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark 3 Danish Multiple Sclerosis Center, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark University of Oxford, UNITED KINGDOM 10 Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark 12 Sanofi, Copenhagen, Denmark 8 Slagelse/Odense University Hospital, Odense, Denmark 11 Sanofi, Amsterdam, The Netherlands 2 The Danish Multiple Sclerosis Registry, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark |
| AuthorAffiliation_xml | – name: 11 Sanofi, Amsterdam, The Netherlands – name: 4 The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark – name: 5 Aarhus University Hospital, Aarhus, Denmark – name: 9 Department of Neurology, Hospital of South West Jutland, Esbjerg, Denmark – name: 3 Danish Multiple Sclerosis Center, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark – name: University of Oxford, UNITED KINGDOM – name: 2 The Danish Multiple Sclerosis Registry, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark – name: 10 Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark – name: 6 Hospital of Southern Jutland, Sønderborg, Denmark – name: 7 Aalborg University Hospital, Aalborg, Denmark – name: 12 Sanofi, Copenhagen, Denmark – name: 1 Odense University Hospital, Odense, Denmark – name: 8 Slagelse/Odense University Hospital, Odense, Denmark |
| Author_xml | – sequence: 1 givenname: Viktoria orcidid: 0000-0001-9968-549X surname: Papp fullname: Papp, Viktoria – sequence: 2 givenname: Mathias Due surname: Buron fullname: Buron, Mathias Due – sequence: 3 givenname: Volkert surname: Siersma fullname: Siersma, Volkert – sequence: 4 givenname: Peter Vestergaard surname: Rasmussen fullname: Rasmussen, Peter Vestergaard – sequence: 5 givenname: Zsolt surname: Illes fullname: Illes, Zsolt – sequence: 6 givenname: Matthias surname: Kant fullname: Kant, Matthias – sequence: 7 givenname: Claudia surname: Hilt fullname: Hilt, Claudia – sequence: 8 givenname: Zsolt surname: Mezei fullname: Mezei, Zsolt – sequence: 9 givenname: Homayoun orcidid: 0000-0002-3019-8826 surname: Roshanisefat fullname: Roshanisefat, Homayoun – sequence: 10 givenname: Tobias orcidid: 0000-0002-7682-2188 surname: Sejbæk fullname: Sejbæk, Tobias – sequence: 11 givenname: Arkadiusz surname: Weglewski fullname: Weglewski, Arkadiusz – sequence: 12 givenname: Janneke surname: van Wingerden fullname: van Wingerden, Janneke – sequence: 13 givenname: Svend Sparre orcidid: 0000-0003-4497-3616 surname: Geertsen fullname: Geertsen, Svend Sparre – sequence: 14 givenname: Stephan orcidid: 0000-0001-9482-1771 surname: Bramow fullname: Bramow, Stephan – sequence: 15 givenname: Finn surname: Sellebjerg fullname: Sellebjerg, Finn – sequence: 16 givenname: Melinda surname: Magyari fullname: Magyari, Melinda |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34003862$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tu1DAQhiNURA_wBggsISG42MWHHBwukKpyqlRUqS3cWo5jb7xy4sV2KH0dnpTZ7m61W1WI5CKjyTe_Pb9mDrO9wQ86y54TPCWsIu_mfgyDdNMFpKeYFphT_Cg7IDWjk5JitrcV72eHMc4xLhgvyyfZPssxhpAeZH8utHSTax9ci_yYlO91RMYHJBHEC6eTRoNM1g_XttWQ63xIyBvU-6BR6uSAGMUYJR2scePge8AmKWiZdIv60SULIigqp4OPNqIFiOkhRWQHdNVp9FEONnbo24a8vCMv9MzGFG6eZo-NdFE_W3-Psu-fP12dfJ2cnX85PTk-m6iypmmSly1XeaFY2xQlKRolS0xaVuW1YY3JC2yYNropKp4bZhhh8BCjyqpVRcEBOspernQXzkextjcKWlDOK8pLDsTpimi9nItFsL0MN8JLK24TPsyEDMlCByJXjCvCtKqVzmnR8Kpm4DpvZF3R3NSg9WF92tj0ulXgSZBuR3T3z2A7MfO_BCcM10UJAm_WAsH_HHVMordRaefkoP24uncNZL0869U99OHu1tRMQgN2MB7OVUtRcVyWlMC9yVJr-gAFb6t7q2AWjYX8TsHbnQJgkv6dZnKMUZxeXvw_e_5jl329xXYwxqmL3o3LWY274Ittp-8s3iwBAO9XgILBi0EboWy6nXlozTpBsFhu3MY0sdw4sd44KM7vFW_0_1n2FylUMZs |
| CitedBy_id | crossref_primary_10_1007_s00415_023_11644_y crossref_primary_10_1177_23982128231185290 crossref_primary_10_1177_17562864241252722 crossref_primary_10_3389_fimmu_2024_1343531 crossref_primary_10_3389_fneur_2021_727586 crossref_primary_10_1177_20552173221077185 crossref_primary_10_1016_j_neurol_2022_09_006 crossref_primary_10_1007_s40120_022_00384_2 crossref_primary_10_1007_s00415_022_11118_7 crossref_primary_10_1136_jnnp_2023_333265 crossref_primary_10_2147_CEOR_S401687 crossref_primary_10_1016_j_ensci_2022_100396 crossref_primary_10_1016_j_neurop_2023_100133 crossref_primary_10_3389_fneur_2023_1274194 |
| Cites_doi | 10.1007/s40265-019-01135-8 10.1212/NXI.0000000000000379 10.1177/1932296819832661 10.1016/j.msard.2020.102438 10.1016/j.msard.2020.102521 10.1016/j.msard.2018.09.017 10.3389/fimmu.2018.02706 10.1016/S1474-4422(17)30470-2 10.1177/1756285617722500 10.1136/bmjopen-2018-028133 10.1177/1352458519855722 10.1212/WNL.0b013e31821e559d 10.1177/1352458519843055 10.2217/cer-2018-0135 10.1056/NEJMoa1014656 10.1177/1756286419835077 10.1016/S1474-4422(13)70308-9 10.1016/j.msard.2019.03.022 10.1016/j.msard.2021.102813 10.3389/fnagi.2018.00238 10.1016/S1474-4422(14)70191-7 10.1038/nrneurol.2016.188 10.1212/WNL.0000000000007314 10.1001/archneurol.2010.150 10.1016/j.msard.2017.07.006 10.1007/s10072-020-04367-9 10.2147/CLEP.S99500 10.1007/s40265-014-0212-x 10.1212/NXI.0000000000000390 10.1016/j.msard.2019.05.014 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2021 Public Library of Science 2021 Papp et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 Papp et al 2021 Papp et al |
| Copyright_xml | – notice: COPYRIGHT 2021 Public Library of Science – notice: 2021 Papp et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 Papp et al 2021 Papp et al |
| DBID | AAYXX CITATION NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0250820 |
| DatabaseName | CrossRef PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) SciTech Premium Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Database ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Public Health |
| DocumentTitleAlternate | Complete nationwide cohort of teriflunomide-treated multiple sclerosis patients in the DMSR |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2528872868 oai_doaj_org_article_4c38c13ec9ce425b87933408ba9724f9 PMC8130956 A662172419 34003862 10_1371_journal_pone_0250820 |
| Genre | Journal Article |
| GeographicLocations | Denmark Jutland Aarhus Denmark |
| GeographicLocations_xml | – name: Denmark – name: Jutland – name: Aarhus Denmark |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ADRAZ BBORY IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c692t-46d8c45c3db5615bca601d3749f3bf450f3efeb5784f3f3133331fc67dc5589f3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Feb 05 03:14:00 EST 2023 Wed Aug 27 01:19:07 EDT 2025 Thu Aug 21 14:31:42 EDT 2025 Fri Sep 05 13:43:23 EDT 2025 Fri Jul 25 10:16:56 EDT 2025 Tue Jun 17 21:19:53 EDT 2025 Tue Jun 10 20:42:20 EDT 2025 Fri Jun 27 03:47:09 EDT 2025 Fri Jun 27 04:59:05 EDT 2025 Thu May 22 21:23:10 EDT 2025 Wed Feb 19 02:28:55 EST 2025 Tue Jul 01 02:41:57 EDT 2025 Thu Apr 24 22:55:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-46d8c45c3db5615bca601d3749f3bf450f3efeb5784f3f3133331fc67dc5589f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: This study was funded by Sanofi. VP: has received support for scientific meetings from Merck and Sanofi Genzyme and honoraria for lecturing from Alexion. MDB: None. VS: None. PVR: has served on scientific advisory board for Biogen, Sanofi, Roche, Novartis, Merck, and Alexion, has received honoraria for lecturing from Biogen, Merck, Novartis, Roche, has received support for congress participation from Biogen, Genzyme, Roche, Merck, Novartis. ZI: has served on scientific advisory boards, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, Merck, Roche, Sanofi Genzyme. MK: None. CH: has served on scientific advisory board for Biogen, Sanofi, Roche, Novartis, has received honoraria for lecturing from Biogen, Merck, Novartis, Sanofi, Genzyme, has received support for congress participation from Biogen and Roche. ZM: None. HR: None. TS: has served on scientific advisory boards, received support for congress participation, received speaker honoraria and received research support from Biogen and Novartis, and received support for congress participation by Roche. AW: has served on scientific advisory board for Merck, Biogen and Roche, has received honoraria for lecturing and publications from Sanofi Genzyme, Merck, Roche and has received support for congress participation from Biogen, Genzyme, Teva, Merck and Roche. JvW and SSG are employees of Sanofi. SB: has received support for congress participation from Biogen and Roche. FS: has served on scientific advisory boards, been on the steering committees of clinical trials, served as a consultant, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, EMD Serono, Merck, Novartis, Roche, Sanofi Genzyme and Teva. MM: has served on scientific advisory board for Biogen, Sanofi, Roche, Novartis, Merck, Abbvie, Alexion has received honoraria for lecturing from Biogen, Merck, Novartis, Sanofi, Genzyme, has received research support and support for congress participation from Biogen, Genzyme, Roche, Merck, Novartis. The specific roles of these authors are articulated in the ‘author contributions’ section. With reference to PLOS ONE policies on sharing data and materials, we confirm that this does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| ORCID | 0000-0001-9482-1771 0000-0003-4497-3616 0000-0002-7682-2188 0000-0002-3019-8826 0000-0001-9968-549X |
| OpenAccessLink | https://www.proquest.com/docview/2528872868?pq-origsite=%requestingapplication% |
| PMID | 34003862 |
| PQID | 2528872868 |
| PQPubID | 1436336 |
| PageCount | e0250820 |
| ParticipantIDs | plos_journals_2528872868 doaj_primary_oai_doaj_org_article_4c38c13ec9ce425b87933408ba9724f9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8130956 proquest_miscellaneous_2528909599 proquest_journals_2528872868 gale_infotracmisc_A662172419 gale_infotracacademiconefile_A662172419 gale_incontextgauss_ISR_A662172419 gale_incontextgauss_IOV_A662172419 gale_healthsolutions_A662172419 pubmed_primary_34003862 crossref_citationtrail_10_1371_journal_pone_0250820 crossref_primary_10_1371_journal_pone_0250820 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-05-18 |
| PublicationDateYYYYMMDD | 2021-05-18 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-18 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2021 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | M Magyari (pone.0250820.ref027) 2016; 8 P O’Connor (pone.0250820.ref005) 2011; 365 JP Brown (pone.0250820.ref016) 2019; 9 R Lanzillo (pone.0250820.ref021) 2020; 41 BA Kallmann (pone.0250820.ref020) 2019; 12 R Zivadinov (pone.0250820.ref022) 2019; 8 A Bar-Or (pone.0250820.ref004) 2014; 74 PK Coyle (pone.0250820.ref017) 2018; 26 S Vukusic (pone.0250820.ref024) 2020; 26 AE Miller (pone.0250820.ref012) 2019; 33 A Musella (pone.0250820.ref031) 2018; 10 RA Rudick (pone.0250820.ref029) 2010; 67 AJ Thompson (pone.0250820.ref033) 2018; 17 AE Miller (pone.0250820.ref011) 2020; 46 DC Klonoff (pone.0250820.ref015) 2020; 14 MP Sormani (pone.0250820.ref010) 2017; 4 T Gholipour (pone.0250820.ref032) 2011; 76 AE Miller (pone.0250820.ref013) 2017; 10 P Vermersch (pone.0250820.ref023) 2020; 46 pone.0250820.ref002 MD Buron (pone.0250820.ref025) 2019; 92 EW Radue (pone.0250820.ref008) 2017; 4 M Trojano (pone.0250820.ref014) 2017; 13 AE Miller (pone.0250820.ref007) 2014; 13 M Magyari (pone.0250820.ref028) 2020 JB Andersen (pone.0250820.ref026) 2018; 9 pone.0250820.ref001 PK Coyle (pone.0250820.ref019) 2019; 31 P Sorensen (pone.0250820.ref030) 2021; 50 T Sprenger (pone.0250820.ref009) 2020; 26 PK Coyle (pone.0250820.ref018) 2017; 17 C Confavreux (pone.0250820.ref006) 2014; 13 LJ Scott (pone.0250820.ref003) 2019; 79 |
| References_xml | – volume: 79 start-page: 875 issue: 8 year: 2019 ident: pone.0250820.ref003 article-title: Teriflunomide: A Review in Relapsing–Remitting Multiple Sclerosis publication-title: Drugs doi: 10.1007/s40265-019-01135-8 – volume: 4 start-page: e379 year: 2017 ident: pone.0250820.ref010 article-title: Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO publication-title: Neurol Neuroimmunol neuroinflammation doi: 10.1212/NXI.0000000000000379 – volume: 14 start-page: 345 year: 2020 ident: pone.0250820.ref015 article-title: The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics publication-title: J Diabetes Sci Technol doi: 10.1177/1932296819832661 – volume: 46 start-page: 102438 year: 2020 ident: pone.0250820.ref011 article-title: Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2020.102438 – volume: 46 start-page: 102521 year: 2020 ident: pone.0250820.ref023 article-title: An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017 publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2020.102521 – volume: 26 start-page: 211 year: 2018 ident: pone.0250820.ref017 article-title: Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2018.09.017 – volume: 9 start-page: 2706 year: 2018 ident: pone.0250820.ref026 article-title: Pregnancy outcomes in men and women treated with teriflunomide. A population-based nationwide Danish register study publication-title: Front Immunol doi: 10.3389/fimmu.2018.02706 – start-page: e01921 year: 2020 ident: pone.0250820.ref028 article-title: The Danish Multiple Sclerosis Registry publication-title: Brain Behav – volume: 17 start-page: 162 year: 2018 ident: pone.0250820.ref033 article-title: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30470-2 – volume: 10 start-page: 381 year: 2017 ident: pone.0250820.ref013 article-title: Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience publication-title: Ther Adv Neurol Disord doi: 10.1177/1756285617722500 – volume: 9 start-page: e028133 year: 2019 ident: pone.0250820.ref016 article-title: Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017 publication-title: BMJ Open doi: 10.1136/bmjopen-2018-028133 – volume: 26 start-page: 1207 year: 2020 ident: pone.0250820.ref009 article-title: Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide publication-title: Mult Scler doi: 10.1177/1352458519855722 – volume: 76 start-page: 1996 year: 2011 ident: pone.0250820.ref032 article-title: Demographic and clinical characteristics of malignant multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e31821e559d – volume: 26 start-page: 829 year: 2020 ident: pone.0250820.ref024 article-title: Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience publication-title: Mult Scler doi: 10.1177/1352458519843055 – ident: pone.0250820.ref001 – volume: 8 start-page: 305 year: 2019 ident: pone.0250820.ref022 article-title: Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study publication-title: J Comp Eff Res doi: 10.2217/cer-2018-0135 – volume: 365 start-page: 1293 issue: 14 year: 2011 ident: pone.0250820.ref005 article-title: Randomized trial of oral teriflunomide for relapsing multiple sclerosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1014656 – volume: 12 start-page: 1756286419835077 year: 2019 ident: pone.0250820.ref020 article-title: Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study publication-title: Ther Adv Neurol Disord doi: 10.1177/1756286419835077 – volume: 13 start-page: 247 year: 2014 ident: pone.0250820.ref006 article-title: Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(13)70308-9 – volume: 31 start-page: 157 year: 2019 ident: pone.0250820.ref019 article-title: Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2019.03.022 – volume: 50 start-page: 102813 year: 2021 ident: pone.0250820.ref030 article-title: Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2021.102813 – volume: 10 start-page: 238 year: 2018 ident: pone.0250820.ref031 article-title: Interplay between age and neuroinflammation in multiple sclerosis: Effects on motor and cognitive functions publication-title: Front Aging Neurosci doi: 10.3389/fnagi.2018.00238 – volume: 13 start-page: 977 year: 2014 ident: pone.0250820.ref007 article-title: Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70191-7 – volume: 13 start-page: 105 year: 2017 ident: pone.0250820.ref014 article-title: Treatment decisions in multiple sclerosis-insights from real-world observational studies publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2016.188 – volume: 92 start-page: E1811 year: 2019 ident: pone.0250820.ref025 article-title: Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study publication-title: Neurology doi: 10.1212/WNL.0000000000007314 – volume: 67 start-page: 1329 year: 2010 ident: pone.0250820.ref029 article-title: Disability progression in a clinical trial of relapsing-remitting multiple sclerosis eight-year follow-up publication-title: Arch Neurol doi: 10.1001/archneurol.2010.150 – volume: 17 start-page: 107 year: 2017 ident: pone.0250820.ref018 article-title: Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2017.07.006 – volume: 41 start-page: 3235 year: 2020 ident: pone.0250820.ref021 article-title: A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting publication-title: Neurol Sci doi: 10.1007/s10072-020-04367-9 – volume: 8 start-page: 549 year: 2016 ident: pone.0250820.ref027 article-title: The Danish multiple sclerosis treatment register publication-title: Clin Epidemiol doi: 10.2147/CLEP.S99500 – ident: pone.0250820.ref002 – volume: 74 start-page: 659 issue: 6 year: 2014 ident: pone.0250820.ref004 article-title: Teriflunomide and its mechanism of action in multiple sclerosis publication-title: Drugs doi: 10.1007/s40265-014-0212-x – volume: 4 start-page: e390 issue: 5 year: 2017 ident: pone.0250820.ref008 article-title: Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA publication-title: Neurol Neuroimmunol NeuroInflammation doi: 10.1212/NXI.0000000000000390 – volume: 33 start-page: 131 year: 2019 ident: pone.0250820.ref012 article-title: Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2019.05.014 |
| SSID | ssj0053866 |
| Score | 2.4453285 |
| Snippet | Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a... Objective Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a... ObjectiveTeriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a... About the Authors: Viktoria Papp Roles Conceptualization, Data curation, Investigation, Methodology, Validation, Writing – original draft, Writing – review &... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0250820 |
| SubjectTerms | Biology and Life Sciences Care and treatment Cladribine Copolymer 1 Demographics Demography Diagnosis Editing Funding Health risks Interferon Medical treatment Medicine and Health Sciences Methodology Mitoxantrone Monoclonal antibodies Multiple sclerosis Neurology Oral diseases Patients People and places Public health Research and Analysis Methods Rituximab Side effects Statistical analysis |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELXQnrggyleXFjAICTikTWIndo4FURWkgrSlqLfIcex2pVWyajbq_-kvZcZ2og2qVA5c45comRmPx87MG0LeVznE8IWqI6F5HHFl40ham0QagoWqVjZVKdYOn_7IT87594vsYqvVF-aEeXpgL7hDrpnUCTO60Absq5JgUIzHslKFSLl1pXuwjA2bKe-DYRbneSiUYyI5DHo5WLeNOcBVX2J_762FyPH1j155tl613V0h59-Zk1tL0fFj8ijEkPTIv_sOeWCaJ2QnzNKOfgxU0p-ektsFxIGRY0Wlbb8B64JxCFOpoi6XHCJm6o8Db5a1odgt93pDW0sx_ZbiqTplYOAUCZ3tqscS5tpELjnd1HRIRqQdvAZ85LKjgaa1o8uGggVSrGDvrujpgDwbkQtz6RrNPSPnx19_fTmJQleGSOdFuol4XkvNM83qCmKvrNIK9nQ1E7ywrLI8iy0z1lTgCbhllsEemLHE6lzUOsskgJ6TWQN62CXUKmsVNxXoGByJAJUWooAYrLbggWMj5oQNKip1oCzHzhmr0v2HE7B18RIvUbFlUOycRONda0_ZcQ_-M2p_xCLhtrsAZlgGMyzvM8M5eYO2U_rq1dFtlEd5ji3AeAKIdw6BpBsNZvVcqr7rym8_f_8D6GwxAX0IINuCOLQKlRTwTUjmNUHuT5DgOvRkeBctfZBKV6ZZCotOKnMJdw7Wf_fw23EYH4qZeo1pe48p8HAZnv7CT5ZRsiCwGGZmOidiMo0mop-ONMsrx3kuIdaCrfzL_6GrPfIwxcwk5OCV-2S2ue7NKwgtN9Vr50X-APNUelc priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZguSAhRMujCwUMQgIObpPYSZwTKoilIBWkLUW9RYkf25VWybLJiv_DL2XGcUKDKuAaf4lsz8PjyTwIeVEmYMNnhWapEgEThQ2YtDZkCoyFUhc2KiLMHT75nByfiU_n8bl3uDU-rLLXiU5R61qhj_wwiiOQh0gm8s36O8OuUfh31bfQuE5uhBFwEmaKzz70mhhkOUl8uhxPw0NPnYN1XZkDPPsldvm-dBy5qv2Dbp6sV3VzleH5Z_zkpQNpdofc9pYkPepIv0OumWqX3OrccLTLLtolO152G_rKF5h-fZf8nMMoc7VSab1tYf0wDsYrLaiLMAc7mnZOwh9LbSj20N20tLYUg3Ip-topB7anWObZrraY2KwNcyHrRtM-RJE2MC1Y9LKhvnhrQ5cVBb6kmNfeXNCTHnk6IOdm4drP3SNns_df3x0z36uBqSSLWiYSLZWIFdclWGRxqQq46Wmeiszy0oo4sNxYU4J-EJZbDjdjzkOrklSrOJYAuk8mFdBlj1BbWFsIUwrFQb2kZZFlaQaWmbaglwOTTgnvSZYrX8gc-2mscvd3LoULTUeBHAmde0JPCRveWneFPP6Bf4vcMGCxDLd7UG8WuZfqHKYoVciNypQB5VdK0HZcBBLmnEbCZlPyFHkp73JaB2WSHyUJNgYTISCeOwSW4qgw1mdRbJsm__jl23-ATucj0EsPsjVshyp8fgWsCUt8jZD7IyQoFDUa3kPO73elyX-LHrzZS8PVw8-GYfwoxu9Vpt52mAxdzvD1B53wDDsLGxaApEZTko7EarT145FqeeEqoUuwwOCC__Dv03pEbkYYiYQ1d-U-mbSbrXkMpmRbPnH64heycHdv priority: 102 providerName: ProQuest |
| Title | Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34003862 https://www.proquest.com/docview/2528872868 https://www.proquest.com/docview/2528909599 https://pubmed.ncbi.nlm.nih.gov/PMC8130956 https://doaj.org/article/4c38c13ec9ce425b87933408ba9724f9 http://dx.doi.org/10.1371/journal.pone.0250820 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: HH5 dateStart: 20060101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KQ8 dateStart: 20060101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KQ8 dateStart: 20061001 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: ABDBF dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DIK dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: GX1 dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: RPM dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Technology Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8FG dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/technologycollection1 providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1932-6203 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M48 dateStart: 20061201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe27oUXxPhaxygGIQEPqZLYiZMHhLZpZSB1oI6ivkWJY3eVqqQ0rYB_h7-UO8eJCCpiL3mIf7aS8935bN8HIS-zEGz4OM0dIbnr8FS7TqS150gwFrI81X7qY-zw-Cq8nPKPs2C2R5qarZaA1c6tHdaTmq6Xwx_ffr4DgX9rqjYIr-k0XJWFGuKaDqvaPjmAtclHPh_z9l4BpNvcXqLV4oS-y2ww3b9G6SxWJqd_q7l7q2VZ7TJL__au_GO5Gt0jd62dSU9rxjgke6q4Tw6tJFf0tU03_eYB-TUBW9ExmVNpud0AB0I7mLI0pcbfHKxqWh8Zfl_kimJF3fWGlpqiiy7Fk3fKQAgoJn3Wyy2GOefKMQ7sKqeNwyKt4DPgJxcVtalcK7ooKHApxSj36oaOG-R1i5youSlG95BMRxdfzi8dW7nBkWHsbxwe5pHkgWR5BvZZkMkU9n05EzzWLNM8cDVTWmWgLbhmmsE-mTFPy1DkMggiAD0ivQLm4YhQnWqdcpVxyUDZiCyNYxGDnZZr0NKuEn3CmilKpE1rjtU1lom5qxOwvakpnuDEJnZi-8Rpe63qtB7_wZ_h7LdYTMptXpTreWJlPIFPjKTHlIylAlWYRaD7GHcj-Gbhcx33yTPknaSOcG1VS3IahlgmjHuAeGEQmJijQM-febqtquTDp6-3AF1POqBXFqRLIIdMbbQF_BMm_OogTzpIUC-y03yEnN5QpUr8wIeFyY_CCHo23L-7-XnbjIOiN1-hym2NifEAGkZ_XAtLS1kgmAtS6veJ6IhRh_TdlmJxY_KiR2CPwXb_-DZEfELu-OidhHl4oxPS26y36imYl5tsQPbFTMAzOvfwOXo_IAdnF1efJwNzYDMwGuU37DCBNQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGeQAJITYuKwxmEAh48JbGTuI8IDQuU8vWIXUb6ltIHLurVCWlaTXxd_gB_EbOSZywoAl42WvOF8vxufjYORdCnic--PBhnLJACYeJ2DhMGtNjCpyFJI2NG7uYOzw88vun4tPYG6-Rn3UuDIZV1jaxNNRprvCOfNf1XNAHV_ry7fwbw65R-He1bqFRicWB_n4OR7bizeAD8PeF6-5_PHnfZ7arAFN-6C6Z8FOphKd4moDv4CUqhjNJygMRGp4Y4TmGa6MTkGRhuOFwhuO8Z5QfpMrzJIBg3GvkuuCOwFr9wbg54IHt8H2bnseD3q6Vhp15nukd9DUkdhW_sP2VXQKavaAzn-XFZY7un_GaFzbA_TvktvVc6V4lautkTWcb5FZ17UerbKYNsm5tRUFf2YLWr--SHyOgsrI2K81XS1hvoIOzTGNaRrSD306rS8nzaaop9uxdLGluKAYBU7zbpxzUjGJZaTNbYSJ1qlkZIq9TWodE0gKmBR89LagtFlvQaUZBDyjm0RdndFgjjxvkSE_Kdnf3yOmVcPE-6WTAl01CTWxMLHQiFLBUBkkchkEInmBqYB9wdNAlvGZZpGzhdOzfMYvKv4EBHKAqDkTI6MgyuktY89a8KhzyD_w7lIYGi2W_ywf5YhJZKxLBFKXqca1CpcHYJhKsKxeOhDkHrjBhl2yjLEVVDm1jvKI938dGZKIHiGclAkt_ZBhbNIlXRRENPn_5D9DxqAV6aUEmh-VQsc3ngG_CkmIt5FYLCQZMtcibKPn1qhTRb1WHN2ttuJz8tCHjoBgvmOl8VWFCvOKG0R9UytOsLCyYA5rqdknQUqvW0rcp2fSsrLwuweMLPf_h36e1TW70T4aH0eHg6OARueliFBTW-5VbpLNcrPRjcGOXyZPSdlDy9aqN1S-EabQ5 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLZGkRASQmz8rDCYQSDgImsaO3FygdBgVCtjA3UM9c4kjt1VqpLStJp4HR6Dp-OcxAkLmoCb3dZfItfnnM_Hzvkh5GkSgA8fxakjFHcdHhvXCY3pOwqchSSNjRd7mDt8eBTsn_D3Y3-8Rn7WuTAYVllzYknUaa7wjrzn-R7YgxcGYc_YsIhPe4PX828OdpDCL611O41KRQ709zM4vhWvhnsg62eeN3j3-e2-YzsMOCqIvKXDgzRU3FcsTcCP8BMVw_kkZYJHhiWG-65h2ugEtJobZhic5xjrGxWIVPl-CCB47xVyVTDOMJxMjJvDHvBIENhUPSb6PasZO_M80zvod4TYYfzcVlh2DGj2hc58lhcXOb1_xm6e2wwHt8hN68XS3Urt1smazjbIjeoKkFaZTRtk3fJGQV_Y4tYvb5MfIxh1yjqtNF8tYe1hHBxnGtMyuh18eFpdUJ5NU02xf-9iSXNDMSCY4j0_ZWByFEtMm9kKk6pT7ZTh8jqldXgkLWBa8KenBbWFYws6zSjYBMWc-uKUHtbI4wY50pOy9d0dcnIpUrxLOhnIZZNQExsTc51wxYDaRBJHkYjAK0wN7AmuFl3CapFJZYuoYy-PmSy_DAo4TFUSkChoaQXdJU7z1LwqIvIP_BvUhgaLJcDLH_LFRFpGkTDFUPWZVpHSQLxJCEzLuBvCnIXHTdQl26hLssqnbYhM7gYBNiXjfUA8KRFYBiRDg5rEq6KQw49f_gN0PGqBnluQyWE5VGxzO-A_YXmxFnKrhQQyU63hTdT8elUK-dvs4cnaGi4eftwM40sxdjDT-arCRHjdDW-_VxlPs7KwYC5YqtclomVWraVvj2TT07IKewjeX-QH9_8-rW1yDWhKfhgeHTwg1z0MiMLSv-EW6SwXK_0QPNpl8qikDkq-XjZX_QL9J7h0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-world+outcomes+for+a+complete+nationwide+cohort+of+more+than+3200+teriflunomide-treated+multiple+sclerosis+patients+in+The+Danish+Multiple+Sclerosis+Registry&rft.jtitle=PloS+one&rft.au=Papp%2C+Viktoria&rft.au=Buron%2C+Mathias+Due&rft.au=Siersma%2C+Volkert&rft.au=Rasmussen%2C+Peter+Vestergaard&rft.date=2021-05-18&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=16&rft.issue=5&rft.spage=e0250820&rft_id=info:doi/10.1371%2Fjournal.pone.0250820&rft.externalDBID=IOV&rft.externalDocID=A662172419 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |